XML 61 R44.htm IDEA: XBRL DOCUMENT
v3.24.1

Schedule of Contractual Clinical Trials (Details) | 12 Months Ended
--- | ---
Dec. 31, 2023 USD ($) Integer
Other Commitments [Line Items] |  |
Remaining financial contractual commitment | $ | $ 6,013,000 |
Phase 1b [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer |
Estimated Start Date | March 2021 |
Estimated End Date | March 2026 |
Remaining financial contractual commitment | $ | $ 2,433,000 |
Phase 1b [Member] | Minimum [Member] |  |
Other Commitments [Line Items] |  |
Number of Patients in Trial | 14 |
Phase 1b [Member] | Maximum [Member] |  |
Other Commitments [Line Items] |  |
Number of Patients in Trial | 36 |
Phase 1b Two [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with doxorubicin in sarcoma |
Estimated Start Date | June 2023 |
Estimated End Date | June 2024 |
Remaining financial contractual commitment | $ | $ 3,580,000 |
Phase 1b Two [Member] | Minimum [Member] |  |
Other Commitments [Line Items] |  |
Number of Patients in Trial | 9 |
Phase 1b Two [Member] | Maximum [Member] |  |
Other Commitments [Line Items] |  |
Number of Patients in Trial | 18 |
Phase 0 Pharmacology Study [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 in high grade gliomas | [1]
Estimated Start Date | January 2019 | [1]
Estimated End Date | August 2022 | [1]
Number of Patients in Trial | 7 | [1]
Randomized Phase 2 [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | Doxorubicin with or without LB-100 in sarcoma | [2]
Estimated Start Date | July 2024 | [2]
Estimated End Date | June 2026 | [2]
Number of Patients in Trial | 150 | [2]
Phase 1b/2 [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with dostarlimab in ovarian clear cell carcinoma | [1]
Estimated Start Date | March 2024 | [1]
Estimated End Date | December 2025 | [1]
Number of Patients in Trial | 21 | [1]
[1] | There is no remaining financial contractual commitment associated with this clinical trial.
[2] | The financial contractual commitment of the GEIS Randomized Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .

X
- Definition Clinical trial description. + References No definition available. + Details
Name: | LIXT_ClinicalTrialDescription
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual clinical trial period end date + References No definition available. + Details
Name: | LIXT_ContractualClinicalTrialPeriodEndDate
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual clinical trial period start date. + References No definition available. + Details
Name: | LIXT_ContractualClinicalTrialPeriodStartDate
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patient in trial. + References No definition available. + Details
Name: | LIXT_NumberOfPatientInTrial
Namespace Prefix: | LIXT_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseZeroPharmacologyStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |